Amicus Therapeutics, Inc. (FOLD)

Market Cap	2.92B
Revenue (ttm)	423.49M
Net Income (ttm)	-147.07M
Shares Out	296.20M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	4,074.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,046,747
Open	9.76
Previous Close	9.80
Day's Range	9.68 - 9.87
52-Week Range	9.02 - 14.57
Beta	0.73
Analysts	Buy
Price Target	17.14 (+74.01%)
Earnings Date	Aug 6, 2024

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and Glaxo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 517
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD

Financial Performance

In 2023, FOLD's revenue was $399.36 million, an increase of 21.30% compared to the previous year's $329.23 million. Losses were -$151.58 million, -35.92% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $17.14, which is an increase of 74.01% from the latest price.

Price Target

$17.14

(74.01% upside)

Analyst Consensus: Buy